Immunovant, Inc.

NasdaqGS:IMVT Stock Report

Market Cap: US$5.2b

Immunovant Valuation

Is IMVT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of IMVT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: Insufficient data to calculate IMVT's future cash flow value for valuation analysis.

Significantly Below Future Cash Flow Value: Insufficient data to calculate IMVT's future cash flow value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IMVT?

Key metric: As IMVT is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for IMVT. This is calculated by dividing IMVT's market cap by their current book value.
What is IMVT's PB Ratio?
PB Ratio5.3x
BookUS$986.14m
Market CapUS$5.24b

Price to Book Ratio vs Peers

How does IMVT's PB Ratio compare to its peers?

The above table shows the PB ratio for IMVT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average20.2x
PTGX Protagonist Therapeutics
7.9x46.02%US$5.1b
ALKS Alkermes
3.2x15.51%US$5.5b
COGT Cogent Biosciences
28.6x56.86%US$5.6b
CELC Celcuity
41.3x57.99%US$4.8b
IMVT Immunovant
5.3x39.07%US$5.2b

Price-To-Book vs Peers: IMVT is good value based on its Price-To-Book Ratio (5.3x) compared to the peer average (20.2x).

Historical Price to Book Ratio

Historical Price to Book Ratio compares a stock's price to the book value of it's equity over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Book Ratio vs Industry

How does IMVT's PB Ratio compare vs other companies in the US Biotechs Industry?

64 CompaniesPrice / BookEstimated GrowthMarket Cap
NKTX Nkarta
0.4x-2.70%US$139.93m
XBIT XBiotech
0.4xn/aUS$74.69m
ETHZ ETHZilla
0.1xn/aUS$66.16m
PMVP PMV Pharmaceuticals
0.5x2.71%US$59.06m
IMVT 5.3xIndustry Avg. 2.6xNo. of Companies70PB0246810+
64 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: IMVT is expensive based on its Price-To-Book Ratio (5.3x) compared to the US Biotechs industry average (2.6x).

Price to Book Ratio vs Fair Ratio

What is IMVT's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IMVT PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio5.3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate IMVT's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IMVT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$25.75
US$40.63
+57.77%
31.73%US$57.00US$16.00n/a16
Feb ’27US$26.00
US$40.31
+55.05%
32.43%US$57.00US$16.00n/a16
Jan ’27US$25.42
US$39.27
+54.47%
35.29%US$57.00US$16.00n/a15
Dec ’26US$22.75
US$38.80
+70.55%
37.78%US$57.00US$16.00n/a15
Nov ’26US$24.68
US$38.33
+55.32%
39.34%US$57.00US$16.00n/a15
Oct ’26US$16.34
US$39.93
+144.36%
35.90%US$57.00US$16.00n/a14
Sep ’26US$14.69
US$40.21
+173.75%
35.39%US$57.00US$16.00n/a14
Aug ’26US$15.71
US$41.64
+165.07%
35.29%US$61.00US$18.00n/a14
Jul ’26US$16.15
US$43.38
+168.64%
31.79%US$61.00US$17.00n/a13
Jun ’26US$14.85
US$43.77
+194.74%
31.44%US$61.00US$17.00n/a13
May ’26US$15.90
US$45.15
+183.99%
29.55%US$61.00US$17.00n/a13
Apr ’26US$15.20
US$46.77
+207.69%
23.26%US$61.00US$20.00n/a13
Mar ’26US$20.60
US$46.92
+127.78%
21.71%US$58.00US$20.00n/a13
Feb ’26US$21.74
US$50.17
+130.76%
10.82%US$58.00US$41.00US$26.0012
Jan ’26US$24.77
US$49.77
+100.93%
10.98%US$58.00US$41.00US$25.4213
Dec ’25US$28.20
US$48.93
+73.52%
12.41%US$58.00US$36.00US$22.7515
Nov ’25US$29.39
US$48.60
+65.36%
12.04%US$60.00US$36.00US$24.6815
Oct ’25US$28.45
US$49.07
+72.48%
9.97%US$60.00US$41.00US$16.3414
Sep ’25US$30.90
US$48.43
+56.73%
8.06%US$57.00US$41.00US$14.6914
Aug ’25US$28.87
US$49.14
+70.22%
7.37%US$57.00US$42.00US$15.7114
Jul ’25US$27.51
US$49.14
+78.64%
7.37%US$57.00US$42.00US$16.1514
Jun ’25US$25.39
US$50.43
+98.62%
6.44%US$57.00US$44.00US$14.8514
May ’25US$28.52
US$50.87
+78.35%
7.59%US$57.00US$40.00US$15.9015
Apr ’25US$31.61
US$50.65
+60.22%
7.29%US$57.00US$40.00US$15.2017
Mar ’25US$35.30
US$50.73
+43.72%
7.73%US$57.00US$40.00US$20.6015
Feb ’25US$36.07
US$50.23
+39.26%
8.05%US$57.00US$40.00US$21.7413
US$40.63
Fair Value
36.6% undervalued intrinsic discount
16
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/15 01:06
End of Day Share Price 2026/02/13 00:00
Earnings2025/12/31
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Immunovant, Inc. is covered by 23 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Jason Matthew GerberryBofA Global Research
Dina RamadaneBofA Global Research